By Patrick Guertin, Global Technical Manager, Cytiva and Yasser Kehail, BioMFG Business Development Leader, Cytiva
As the need for more complex molecules drives a new era of biomanufacturing, there is an increased focus on developing processes with improved security, yield, and process economy. Companies working with legacy equipment face the decision of keeping their existing setup and process or adding modernized technologies to boost efficiency. There may be a perception that there are too many factors to consider when implementing these changes, which could range from simply a change of a single-unit operation to the majority of the process.
The key to adapting existing biomanufacturing processes and creating “smarter” workflows is not just knowing what options are available for doing so. It is also being able to select and successfully implement the ones that will offer the most flexibility while still controlling costs and maintaining quality. However, achieving these goals requires a complete understanding of these novel solutions and technologies, which, when applied appropriately, can push the boundaries of drug development and offer critical advantages in an increasingly competitive industry.